Concepedia

Ronald Christopher

RC

Statistics

Publications

11

Citations

581

H-Index

11

Active since

1984

Affiliations

Takeda (United States)(Current)

Arena Pharmaceuticals (United States)

Takeda (Japan)

Deerfield (United States)

Pharmaceutical Product Development (United States)

Ronald Christopher is an author at Takeda (United States) specializing in pharmacology, pharmacokinetics, and clinical pharmacology.

Publications per year

1984–2017

11

Publications

11

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

Paul S. Covington, Ronald Christopher, Miles P. Davenport et al. · Clinical Therapeutics · 2008 · 138 citations

, , +16

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

Ronald Christopher, Paul S. Covington, Miles P. Davenport et al. · Clinical Therapeutics · 2008 · 129 citations

, , +9

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

Bumsup Lee, Lihong Shi, Daniel B. Kassel et al. · European Journal of Pharmacology · 2008 · 87 citations

, , +13

Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor

Daniel J. Buzard, Sun Hee Kim, Luis Lopez et al. · ACS Medicinal Chemistry Letters · 2014 · 72 citations · Full text

, , +17

Discovery of APD371: Identification of a Highly Potent and Selective CB<sub>2</sub>Agonist for the Treatment of Chronic Pain

Sangdon Han, Lars Thoresen, Jae‐Kyu Jung et al. · ACS Medicinal Chemistry Letters · 2017 · 40 citations · Full text

, , +17

1–5 of 11